ANXA1 and breast carcinoma: Future studies should focus on validating ANXA1's role through functional and in vivo assays, developing targeted therapies such as small‐molecule inhibitors or monoclonal antibodies, and exploring the synergy of ANXA1‐targeted treatments with existing immunotherapies to improve breast cancer patient outcomes.